[0:00–0:33]
On-Screen Title: Opening the blood-brain barrier for glioblastoma with novel device
Dr. Brian Gill: One of the biggest challenges we have in treating glioblastoma is the blood-brain barrier. Here at NewYork-Presbyterian, we are one of the centers for the SONOBIRD clinical trial, which is testing implantation of this device after surgical resection of glioblastoma, of recurrent glioblastoma, specifically, in combination with intravenous delivery of the microbubbles and carboplatin, and to see if that’s more efficacious than standard of care.
[0:34–1:01]
Dr. Brian Gill: The SonoCloud-9 device is an implantable focused ultrasound device, which combines focused ultrasound waves with intravenous delivery of microbubbles to locally open up the blood-brain barrier in the region of the tumor. We were able to do this because we placed the SonoCloud-9 implant right in the region of the craniotomy. As a result, those focused ultrasound waves are directed straight into the tumor bed.
[1:02–1:25]
Dr. Brian Gill: This trial is open and enrolling, and we're really excited to offer it to patients with recurrent glioblastoma. We believe that it builds on the exciting results of the phase one and phase two clinical trials using this device, which showed that it's safe, but also showed some promising data with regards to efficacy. And now this study is going to be able to validate that.
[END]
